Kazia Therapeutics Debt/Equity
What is the Debt/Equity of Kazia Therapeutics?
The Debt/Equity of Kazia Therapeutics Limited is 1.33
What is the definition of Debt/Equity?
Debt to equity ratio is a financial ratio indicating the relative proportion of shareholders’ equity and debt used to finance a company’s assets.
lfy (last fiscal year)
The debt to equity ratio is generally calculated by dividing debt by equity. The D/E ratio is also known as risk, gearing or leverage. The two components are often taken from the firm's balance sheet or statement of financial position (so-called book value), but the ratio may also be calculated using market values for both, if the company's debt and equity are publicly traded, or using a combination of book value for debt and market value for equity financially. Preferred stock can be considered part of debt or equity. Attributing preferred shares to one or the other is partially a subjective decision but will also take into account the specific features of the preferred shares. When used to calculate a company's financial leverage, the debt usually includes only the long-term debt.
Debt/Equity of companies in the Health Care sector on ASX compared to Kazia Therapeutics
What does Kazia Therapeutics do?
Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is GDC-0084, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. The company is also developing Cantrixil, which is being developed for the treatment of ovarian cancer and is in hospitals across Australia and the United States under an Investigational New Drug application. Kazia Therapeutics Limited has collaboration agreements St Jude Childrens Hospital; Dana-Farber Cancer Institute; Alliance for Clinical Trials in Oncology; Memorial Sloan Kettering Cancer Centre; and University of Newcastle. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was founded in 1994 and is based in Sydney, Australia.
Companies with debt/equity similar to Kazia Therapeutics
- Ambertech has Debt/Equity of 1.33
- ORBIS AG has Debt/Equity of 1.33
- Viatris has Debt/Equity of 1.33
- L1 Long Short Fund Ltd has Debt/Equity of 1.33
- Nexus Real Estate Investment Trust has Debt/Equity of 1.33
- Sahyog Multibase has Debt/Equity of 1.33
- Kazia Therapeutics has Debt/Equity of 1.33
- Truscott Mining has Debt/Equity of 1.33
- Diversified Healthcare Trust has Debt/Equity of 1.33
- WWPKG has Debt/Equity of 1.33
- Alimentation Couche-Tard has Debt/Equity of 1.33
- Alimentation Couche-Tard has Debt/Equity of 1.33
- InvesTech has Debt/Equity of 1.33